CoChat

Nanoemulsions for “Nose-to-Brain” Drug Delivery

Open access

The DOI matches its Crossref record; 84 of the 87 references it cites were found in a registry or an index; 59 of the 142 sources its claims cite were checked for support.

Abstract

The blood–brain barrier (BBB) plays a fundamental role in protecting the brain from toxic substances and therefore also controls and restricts the entry of therapeutic agents. The nasal administration of drugs using the nose-to-brain pathway allows direct drug targeting into the brain, avoiding the first-pass effect and bypassing the BBB. Through the nasal route, the drug can access the brain directly along the trigeminal and olfactory nerves, which are located in the upper part of the nasal cavity. Nanoemulsions are formulations belonging to the field of nanomedicine. They consist of emulsions (commonly oil in water) stabilized by one or more surfactants—and eventually co-surfactants—delivered in droplets of small dimensions (sizes of 100–300 nm or less) with a high surface area. A mucoadhesive polymer such as chitosan can be added to the formulation to impair rapid nasal clearance. Nanoemulsions represent promising formulations to deliver drugs directly into the brain through the intranasal route. Therefore, they can be used as a possible alternative to oral administration, avoiding problems such as low solubility in water, poor bioavailability, enzymatic degradation and slow onset of action. This review focuses the present situation in literature regarding the use of nanoemulsions for nose-to-brain targeting, with particular attention to recent publications. Nasal nanoemulsions appear to be effective, non-invasive and safe drug delivery systems to achieve brain targeting for the treatment of neurological diseases.

Overview

CoChat Summary

TL;DR

This review summarizes nanoemulsions (NEs) for nose-to-brain drug delivery, emphasizing oil-in-water systems with droplets around 100–300 nm, mucoadhesive chitosan, and intranasal bypass of the blood–brain barrier. It concludes that nasal NEs are promising, effective, non-invasive, and safe for brain targeting, but clinical studies are still needed.

Key findings

  • NEs are O/W or W/O dispersions stabilized by surfactants, with mean droplet diameter about 100 nm and reported upper limits up to 300 nm; reviewed intranasal formulations are O/W, and chitosan is added as a mucoadhesive and penetration enhancer.
  • The nose-to-brain route bypasses the BBB via olfactory and trigeminal nerves; nasal doses are often 2–10 times lower than oral doses, but about 98% of low-molecular-weight active substances and nearly 100% of macromolecules do not permeate the BBB (Pardridge 2005). The human olfactory region is 2–12.5 cm², about 1.25–10% of the nasal cavity surface, and about 60 μm thick.
  • Across reviewed examples, intranasal NEs improved brain delivery versus nasal solutions, intravenous administration, or oral administration for drugs including risperidone, olanzapine, saquinavir, nimodipine, curcumin, resveratrol, cyclosporine-A, riluzole, selegiline, thymoquinone, paroxetine, quetiapine, zolmitriptan, rivastigmine, and kaempferol. Specific reported values include riluzole NEs with drop size about 24 nm, thymoquinone NEs with mean globule size about 100 nm, and paroxetine NEs with about threefold permeation enhancement versus suspension.
  • Bioimaging showed that NEs of about 100 nm had prolonged nasal residence and were transported through trigeminal and olfactory nerves to the olfactory bulb, whereas larger NEs were cleared faster; particle size played a more important role than chitosan coating or thermosensitive in situ gel thickening.

Methods

  • Narrative review of the literature on NEs for nose-to-brain targeting, with particular attention to recent publications; no systematic search strategy, inclusion/exclusion criteria, or meta-analysis is stated.
  • Data are published studies and examples summarized by drug loaded and therapeutic purpose; Tables 1 and 2 are referenced but not included in the provided text.
  • Main synthesis is qualitative, describing NE composition, excipients, preparation methods, and in vitro, ex vivo, and in vivo outcomes.

Limitations

  • The paper states that clinical studies of these formulations are still needed to demonstrate their appropriateness in clinical practice; it also states that no data seem available on the relevance of oil choice for nasal and especially nose-to-brain administration, and that literature contains confusion in classifying NEs versus microemulsions.
  • Evident from the text: this is a narrative review without systematic search or quantitative synthesis, and the referenced tables are not included in the provided text.
  • Evident from the text: most cited evidence is preclinical, using ex vivo nasal mucosa and rodent models, with no detailed clinical trial results reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics11020084

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The nose as a route for the administration of drugs.
Figure 1 The nose as a route for the administration of drugs.CC BY · PubMed Central
Figure 2 Preparation methods of nanoemulsions (NEs).
Figure 2 Preparation methods of nanoemulsions (NEs).CC BY · PubMed Central

Verification

Claims the paper makes

49 Valid · 4 Not valid · 53 Not checked · 31 Own results and interpretations

58 more claims · 15 with their cited sources checked

Create a free account to see all 137 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 30
  • It may state two separate claims as one. 54

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 84 references

Research works printed but not linked: 1

  1. Niranjan, 2015, Formulation, design and in vitro evaluation of zolmitriptan immediate release tablets using Primojel and Ac-Di-Sol, J. Pharm. Sci. Res., 7, 545

Cited by

See all 269

Metadata

Authors
Bonferoni, M. C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., & Giunchedi, P.
Affiliations
  • University of Pavia (IT)
  • University of Sassari (IT)
Corresponding author
Bonferoni, Maria Cristina
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2019-02-17
Volume
11
Issue
2
Pages
84
ISSN
1999-4923 (ISSN-L)
OpenAlex
W2913486029
Cited by
269
References
87
Citations by year
2026: 29 · 2025: 36 · 2024: 29 · 2023: 53 · 2022: 47 · 2021: 33 · 2020: 33 · 2019: 8
FWCI
2.91
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UnissResearch (Università degli Studi di Sassari) (submittedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords
nanoemulsions, nose-to-brain delivery, blood-brain barrier, intranasal drug delivery, olfactory nerve, trigeminal nerve, surfactants, neurological disorders, brain targeting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanoemulsions for “Nose-to-Brain” Drug Delivery. https://app.cochat.ai/papers/10.3390/pharmaceutics11020084
The paper
Bonferoni, M. C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., & Giunchedi, P. (2019). Nanoemulsions for “Nose-to-Brain” Drug Delivery. Pharmaceutics. https://doi.org/10.3390/pharmaceutics11020084

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.